Literature DB >> 6370068

NIH conference. Systemic lupus erythematosus: insights from animal models.

A D Steinberg, E S Raveché, C A Laskin, H R Smith, T Santoro, M L Miller, P H Plotz.   

Abstract

Systemic lupus erythematosus is a multisystem, antibody-mediated, autoimmune disorder that occurs spontaneously in humans and mice. Genetic factors appear to play an important predisposing role in the disorder: The presence of certain genes may produce a generalized immune abnormality, whereas others may lead to specific autoantibodies. Environmental triggers increase autoantibody production and augment the expression of illness. Bacterial and viral illnesses can provide stimulation by activating macrophages and T cells that, in turn, stimulate B cells. In the absence of normal control mechanisms, the stimulatory process is not suppressed, and excessive stem cell proliferation results in abnormal B-cell proliferation. A trigger for the disease is the signaling of the proliferating B cells to differentiate into antibody-forming cells. Most autoantibody-producing B cells can be eliminated from mice with lupus erythematosus by virtue of the presence of the gene, xid. In addition, administration of an analog of arachidonic acid is an effective treatment for murine lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370068     DOI: 10.7326/0003-4819-100-5-714

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

Review 1.  Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells.

Authors:  Huang-Ge Zhan; John D Mountz; Martin Fleck; Tong Zhou; Hui-Chen Hsu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

3.  Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

4.  Delineation of two defects responsible for T-cell hyporesponsiveness to concanavalin A in MRL congenic mice.

Authors:  R Cameron; J D Waterfield
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

Review 5.  Differential gene expression in autoimmune mice.

Authors:  J D Mountz; J F Mushinski; A D Steinberg
Journal:  Surv Immunol Res       Date:  1985

6.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

7.  Segregation of lymphocyte low-molecular-weight DNA and antinuclear-antibodies in a family with systemic lupus erythematosus in first cousins.

Authors:  H Levcovitz; M A Fletcher; P Phillips; H A Chertok; R Altman; P J Benke
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

8.  Expression of macrophage procoagulant activity in murine systemic lupus erythematosus.

Authors:  E H Cole; J Sweet; G A Levy
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

9.  Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  N Mauermann; Z Sthoeger; H Zinger; E Mozes
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

10.  Cyclophosphamide and 15(S)-15 methyl PGE1 correct the T/B lymphocyte ratios of NZB/NZW mice.

Authors:  D Girard; R M Aloisi; M L Bliven; A C Cunningham; I G Otterness
Journal:  Agents Actions       Date:  1990-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.